A study assessed its efficacy in 12 patients with uterine sarcoma, where recombinant adenovirus-p53 (rAd-p53) was administered alongside chemotherapy including bleomycin, cisplatin, epirubicin, and isocyclophosphamide. This evidence concerns the gene TP53 and uterine corpus sarcoma.